LCTX Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Mai 2024 @ 22:00):

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally...

Stats
Tagesvolumen	602 177
Durchschnittsvolumen	947 408
Marktkapitalisierung	200.13M
EPS	$0 ( 2024-03-07 )
Nächstes Ertragsdatum	( $-0.0400 ) 2024-05-09
Last Dividend	$0.0800 ( 2003-12-15 )
Next Dividend	$0 ( N/A )
P/E	-8.83
ATR14	$0.00400 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Culley Brian M	Buy	1 900 000	Employee Stock Option (Right to Buy)
2024-03-07	Samuel George A. Iii	Buy	650 000	Employee Stock Option (Right to Buy)
2024-03-07	Howe Jill Ann	Buy	650 000	Employee Stock Option (Right to Buy)
2024-02-11	Samuel George A. Iii	Sell	6 076	Restricted Stock Units
2024-02-11	Samuel George A. Iii	Buy	6 076	Common Shares, no par value

INSIDER POWER
98.17
Last 93 transactions
Buy: 20 710 358 \| Sell: 1 476 683

Volumen Korrelation

Lang: -0.46 (neutral)

Kurz: 0.96 (very strong)

Signal:(51.731) Expect same movement, but be aware

Lineage Cell Therapeutics Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Lineage Cell Therapeutics Korrelation - Währung/Rohstoff

0.51
( weak )

0.63
( weak )

0.00
( neutral )

0.19
( neutral )

Lineage Cell Therapeutics Finanzdaten

Annual	2023
Umsatz:	$8.95M
Bruttogewinn:	$7.58M (84.76 %)
EPS:	$-0.120

FY	2023
Umsatz:	$8.95M
Bruttogewinn:	$7.58M (84.76 %)
EPS:	$-0.120

FY	2022
Umsatz:	$14.70M
Bruttogewinn:	$13.98M (95.05 %)
EPS:	$-0.160

FY	2021
Umsatz:	$3.90M
Bruttogewinn:	$2.47M (63.40 %)
EPS:	$-0.260

Financial Reports:

No articles found.

Lineage Cell Therapeutics Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Lineage Cell Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0800	2003-12-15
Last Dividend	$0.0800	2003-12-15
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0800	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-05)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for AMEX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
BOAT	Ex Dividend Junior	2023-06-27	Quarterly	0.00%
EVV	Ex Dividend King	2023-09-08	Monthly	0.00%
NBH	Ex Dividend Knight	2023-09-28	Monthly	0.00%
UTG	Ex Dividend Knight	2023-08-17	Monthly	0.00%
AIVL	Ex Dividend Junior	2023-06-26	Bi-Monthly	0.00%
ENX	Ex Dividend King	2023-09-21	Monthly	0.00%
KDRN	Ex Dividend Junior	2023-06-26	Quarterly	0.00%
SCCB	Ex Dividend Knight	2023-09-14	Quarterly	0.00%
DFUS	Ex Dividend Junior	2023-09-19	Quarterly	0.00%
IHT	Ex Dividend Knight	2023-07-19	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-2.41	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.213	1.200	-7.10	-8.52	[0 - 0.3]
returnOnEquityTTM	-0.313	1.500	-4.59	-6.89	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.14	0.800	4.30	3.44	[1 - 3]
quickRatioTTM	2.02	0.800	2.84	2.27	[0.8 - 2.5]
cashRatioTTM	1.973	1.500	0.148	0.222	[0.2 - 2]
debtRatioTTM	0.0292	-1.500	9.51	-10.00	[0 - 0.6]
interestCoverageTTM	56.86	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.165	2.00	-0.0551	-0.110	[0 - 30]
freeCashFlowPerShareTTM	-0.169	2.00	-0.0847	-0.169	[0 - 20]
debtEquityRatioTTM	0.0465	-1.500	9.81	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.905	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-2.77	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-9.68	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0885	0.800	-2.74	-2.19	[0.5 - 2]
Total Score				-0.295

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-8.51	1.000	-0.960	0	[1 - 100]
returnOnEquityTTM	-0.313	2.50	-2.95	-6.89	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.169	2.00	-0.0564	-0.169	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.165	2.00	-0.0551	-0.110	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.170	1.500	5.54	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.19	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-1.026

Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Echtzeitaktualisierungen für Lineage Cell Therapeutics [LCTX]

Upcoming Earnings Alert

Lineage Cell Therapeutics Dividend Information - No Dividend Player

Dividend Commentary

Top 10 dividend Companies for AMEX

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)